EP4688840A1 - Agonistische geteilte antikörper - Google Patents

Agonistische geteilte antikörper

Info

Publication number: EP4688840A1
Authority: EP; European Patent Office
Prior art keywords: seq; polypeptide; amino acid; acid sequence; antigen binding
Prior art date: 2023-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP24714516.2A

Other languages

English (en)

French (fr)

Inventor

Petra Elisabeth Marilena BALBI

Jack Anthony BATES

Samuele CALABRO

Laura CODARRI DEAK

Stephan Gasser

Guy Georges

Xavier GUERIPEL

Ralf Joerg HOSSE

Christian Klein

Stéphane Gérard Alain LECLAIR

Ekkehard Moessner

Christian Mueller

Diana Angela PIPPIG

Laurene POUSSE

Camilla Elizabeth TREVOR

Pablo UMAÑA FERNÁNDEZ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

F Hoffmann La Roche AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2023-04-03

Filing date

2024-04-02

Publication date

2026-02-11

2024-04-02 Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG

2026-02-11 Publication of EP4688840A1 publication Critical patent/EP4688840A1/de

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)

EP24714516.2A 2023-04-03 2024-04-02 Agonistische geteilte antikörper Pending EP4688840A1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP23166352		2023-04-03
EP23166346		2023-04-03
PCT/EP2024/058832 WO2024208776A1 (en)	2023-04-03	2024-04-02	Agonistic split antibodies

Publications (1)

Publication Number	Publication Date
EP4688840A1 true EP4688840A1 (de)	2026-02-11

Family

ID=90482358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP24714516.2A Pending EP4688840A1 (de)	2023-04-03	2024-04-02	Agonistische geteilte antikörper

Country Status (3)

Country	Link
EP (1)	EP4688840A1 (de)
CN (1)	CN120917044A (de)
WO (1)	WO2024208776A1 (de)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (de)	1991-06-14	2004-09-16	Genentech, Inc., South San Francisco	Humanisierter Heregulin Antikörper
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
ATE299938T1 (de)	1997-05-02	2005-08-15	Genentech Inc	Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
CA2378403A1 (en)	1999-07-26	2001-02-01	Genentech, Inc.	Novel polynucleotides and method for the use thereof
EP2374817B1 (de)	2004-04-13	2017-09-06	F. Hoffmann-La Roche AG	Anti-P-Selectin-Antikörper
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
PT1871805T (pt)	2005-02-07	2019-12-02	Roche Glycart Ag	Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações
TWI671403B (zh)	2005-03-31	2019-09-11	中外製藥股份有限公司	控制組裝之多肽的製造方法
PT1999154E (pt)	2006-03-24	2013-01-24	Merck Patent Gmbh	Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
AU2009204501B2 (en)	2008-01-07	2015-02-12	Amgen Inc.	Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2010245011B2 (en)	2009-04-27	2015-09-03	Oncomed Pharmaceuticals, Inc.	Method for making heteromultimeric molecules
JP5856073B2 (ja)	2009-12-29	2016-02-09	エマージェントプロダクトデベロップメントシアトル，エルエルシー	Ｒｏｎ結合構築体およびその使用方法
WO2011143545A1 (en)	2010-05-14	2011-11-17	Rinat Neuroscience Corporation	Heterodimeric proteins and methods for producing and purifying them
NZ703653A (en)	2010-08-13	2016-09-30	Roche Glycart Ag	Anti-fap antibodies and methods of use
MX352929B (es)	2010-11-05	2017-12-13	Zymeworks Inc	DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
TR201815420T4 (tr)	2011-03-29	2018-11-21	Roche Glycart Ag	Antikor fc varyantları.
RS60499B1 (sr)	2011-12-20	2020-08-31	Medimmune Llc	Modifikovani polipeptidi za bispecifične skelete antitela
MX359411B (es) *	2012-01-13	2018-09-27	Univ Wuerzburg J Maximilians	Complementación funcional bipartita inducida por antígenos, dual.
EP2814587B1 (de)	2012-02-15	2018-05-02	F.Hoffmann-La Roche Ag	Affinitätschromatographie auf fc-rezeptor-basis
ES2740749T3 (es)	2012-04-20	2020-02-06	Merus Nv	Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
CN110087682B (zh) *	2016-12-19	2023-12-15	豪夫迈·罗氏有限公司	用靶向性4-1bb(cd137)激动剂的组合疗法
MX2021003548A (es)	2018-10-01	2021-05-27	Hoffmann La Roche	Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
CA3190415A1 (en)	2020-08-05	2022-02-10	Synthekine, Inc.	Il2rb/il2rg synthetic cytokines
WO2022032025A1 (en) *	2020-08-05	2022-02-10	Synthekine, Inc.	Ifngr binding synthetic cytokines and methods of use

2024
- 2024-04-02 EP EP24714516.2A patent/EP4688840A1/de active Pending
- 2024-04-02 WO PCT/EP2024/058832 patent/WO2024208776A1/en not_active Ceased
- 2024-04-02 CN CN202480023433.0A patent/CN120917044A/zh active Pending

Also Published As

Publication number	Publication date
WO2024208776A1 (en)	2024-10-10
CN120917044A (zh)	2025-11-07

Publication	Publication Date	Title
JP7662516B2 (ja)	2025-04-15	Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
EP3204415B1 (de)	2020-06-17	Bispezifische antikörper gegen cd3epsilon und ror1
US11459404B2 (en)	2022-10-04	Bispecific T cell activating antigen binding molecules
JP7809680B2 (ja)	2026-02-02	癌処置のための多重特異性結合タンパク質
JP2025081307A (ja)	2025-05-27	Ｎｋ細胞結合抗体融合構築物
CN114786708A (zh)	2022-07-22	用于调节免疫细胞功能的突变体白介素-2多肽与抗原结合分子的融合物
US12098203B2 (en)	2024-09-24	Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
TW202219065A (zh)	2022-05-16	免疫活化 Fc 域結合分子
TW202233673A (zh)	2022-09-01	含調節免疫細胞功能之ｃｄ８抗原結合分子之融合物
JP2017520575A (ja)	2017-07-27	二重特異的ヘテロ二量体ダイアボディおよびその使用
CA2896359A1 (en)	2014-09-04	Bispecific t cell activating antigen binding molecules
CN114127112A (zh)	2022-03-01	与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2023159379A (ja)	2023-10-31	Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
US20250163157A1 (en)	2025-05-22	Bispecific antibodies against cd277 and a tumor-antigen
JP2023532807A (ja)	2023-07-31	Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
CN116390948A (zh)	2023-07-04	双功能分子
CN113490690A (zh)	2021-10-08	异源二聚体融合蛋白
JP2026501338A (ja)	2026-01-14	抗ｐｄ－１抗体抗原結合ドメイン及び免疫抱合体
US20200354457A1 (en)	2020-11-12	Bispecific antibodies comprising an antigen-binding site binding to lag3
JP2025524347A (ja)	2025-07-30	ガンマデルタｔ細胞受容体に結合するバリアント抗体
WO2024208777A1 (en)	2024-10-10	All-in-one agonistic antibodies
WO2025041097A1 (en)	2025-02-27	Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
EP4688840A1 (de)	2026-02-11	Agonistische geteilte antikörper
HK40126819A (zh)	2026-01-02	一体化激动性抗体
WO2026013158A1 (en)	2026-01-15	Antibodies binding to constant domains of gamma delta t-cell receptors

Legal Events

Date	Code	Title	Description
2024-04-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: UNKNOWN
2024-10-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2026-01-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2026-01-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2026-02-11	17P	Request for examination filed	Effective date: 20251103
2026-02-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR